Regulus Therapeutics (RGLS) Misses Q3 EPS by 2c

Regulus Therapeutics (NASDAQ: RGLS) reported Q3 EPS of ($0.10), $0.02 worse than the analyst estimate of ($0.08).

As of September 30, 2021, Regulus had $35.8 million in cash and cash equivalents.

For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.

You May Also Be Interested In

• H&R Block (HRB) Tops Q4 EPS by 7c, Offers Guidance
• Black Rock Coffee Bar, Inc. (BRCB) Misses Q2 EPS by 1c
• Canterbury Park (CPHC) Misses Q2 EPS by 3c